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Ambulatory blood pressure (BP) monitoring provides information not only on the BP level but also on the diurnal changes in BP.
In the present review, we summarized the main findings of the International Database on Ambulatory BP in relation to
Cardiovascular Outcome (IDACO) with regard to risk stratification based on BP variability. The predictive accuracy of daytime
and nighttime BP and the night-to-day BP ratio depended on the disease outcome under study and treatment status, and
differed for fatal outcomes compared with the composite of fatal and nonfatal diseases. An exaggerated morning surge,
exceeding the 90th percentile of the population, is an independent risk factor for mortality and cardiovascular and cardiac
events. Conversely, a sleep-trough or preawakening morning surge in systolic BP below 20mmHg is probably not associated with
an increased risk of death or cardiovascular events. BP variability as captured by the average of the daytime and nighttime s.d.
weighted for the duration of the daytime and nighttime interval (s.d.dn) and the average real variability (ARV24) predicted the
outcome, but improved the prediction of the composite of all cardiovascular events by only 0.1%. In conclusion, the IDACO
observations support the concept that BP variability adds to risk stratification, but above all highlight that 24-h ambulatory BP
level remains the main predictor to be considered in clinical practice.
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INTRODUCTION
Ambulatory monitoring allows the registration of blood pressure (BP)
throughout the day in patients engaged in their usual activities.
Ambulatory BP recordings have high reproducibility, are not subject
to digit preference, and avoid the transient rise of a patient’s BP in
response to a medical environment, the so-called white-coat effect.1,2
Collaborative meta-analyses of individual patient data constitute a
powerful research tool to clarify the role of cardiovascular risk factors
in relation to total and cause-specific mortality and morbidity, over
and beyond the prognostic information generated by single-cohort
studies.3,4 The international database on ambulatory BP monitoring5
illustrated to what extent a meta-analysis of individual patient data
can contribute to our understanding of the distribution5,6 and the
diurnal profile5,7 of ambulatory BP across ethnically diverse popula-
tions. This database, constructed in 1993–1994,5 however, lacked a
prospective dimension. We therefore planned to build a shared new
resource of prospective studies conducted in the general population
with the objective of elucidating with great precision to what extent
ambulatory BP improves risk stratification over and beyond conven-
tional BP. We chose IDACO as the acronym for the new International
Database of Ambulatory BP in relation to Cardiovascular Outcome.
Studies were eligible for inclusion if they comprised a random
population sample, if information on the conventional and ambula-
tory BP levels were available at baseline, and if subsequent follow-up
included fatal and nonfatal outcomes. All studies included in the
IDACO received ethics approval and have been previously published
in peer-reviewed journals.6,8–13 All participants provided informed
written consent. In this review, we focused on BP variability,
summarized the state-of-the art before IDACO and also highlighted
what IDACO added to current knowledge.
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DAY-TO-NIGHT BP VARIABILITY
State-of-the-art before IDACO
In 1988, O’Brien et al.14 reported for the first time that an abnormal
circadian BP profile with a less marked decrease in nighttime BP level
led to an increased risk of stroke. Subsequent studies of popula-
tions8,12,15,16 and hypertensive cohorts17–23 generally corroborated that
a raised nocturnal BP predicted a higher rate of cardiovascular
complications. Despite the apparent agreement between these pre-
viously published large-scale studies,8,12,15–23 several potential limita-
tions warranted further clarification of the prognostic accuracy of the
day vs. night ambulatory BP. Many studies considered only fatal
outcomes8,12,21,22 or did not have the power to study cause-specific
cardiovascular end points.8,12,16,20 Investigators dichotomized the
night-to-day BP ratio, and applied different definitions of dipping
status or different daytime and nighttime intervals. Few reports
formally compared the predictive value of the BP at night over and
beyond the daytime value. Finally, in cohorts of patients with
hypertension, antihypertensive drug treatment attenuated the associa-
tion between outcome and BP.18
Information added by IDACO
We aimed to report risk estimates that were independently associated
with the daytime and nighttime BP level. In addition, we investigated
in categorical and continuous analyses whether the night-to-day BP
ratio contained any prognostic information over and beyond the 24-h
BP.24 Table 1 summarizes the number of participants included in this
analysis by ethnicity and country and their baseline characteristics.
When adjusted for daytime BP, nighttime BP predicted the total
and cardiovascular mortality (Table 2). With adjustments applied for
cohort and risk factors, the daytime and nighttime systolic and
diastolic BPs consistently predicted cardiovascular, cardiac and cor-
onary events, and fatal and nonfatal stroke. In fully adjusted models,
with correction for nighttime BP, the systolic daytime BP lost its
prognostic significance for cardiac events, whereas the diastolic day-
time BP became nonsignificant for cardiac and coronary events. When
adjusted for daytime BP, the systolic and diastolic nighttime levels no
longer predicted coronary events (Table 2). Antihypertensive drug
treatment removed the significant association between cardiovascular
events and daytime BP. As in the continuous analyses, the hazard
ratios (HRs) associated with extreme, decreased and reverse dipping
vs. normal dipping showed an increasing risk from extreme to reverse
dipping for mortality, but the results were inconsistent when con-
sidering fatal combined with nonfatal events.
In continuous analyses, the systolic and diastolic night-to-day ratios
significantly predicted total and cardiovascular mortality in models
adjusted for cohort and risk factors. This finding was also noted in
fully adjusted models, which were additionally adjusted for 24-h BP.
The only exception was the fully adjusted association of cardiovascular
mortality with the systolic night-to-day ratio (Table 2). In contrast
with mortality, the systolic and diastolic night-to-day ratios were
inconsistent predictors of fatal combined with nonfatal cardiovascular
events. In fully adjusted models, the systolic night-to-day ratio was not
significant for all combined fatal and nonfatal outcomes investigated.
The diastolic night-to-day ratio was only a significant predictor of all
cardiovascular outcomes, but not of other combined fatal and nonfatal
events (Table 2).
Figure 1 shows Kaplan–Meier survival function estimates for total
mortality and the composite cardiovascular end point by category of
the systolic night-to-day ratio. With adjustments applied for cohort,
cardiovascular risk factors and the 24-h BP, participants with higher
nighttime than daytime BP or with a nondipping nocturnal fall had
higher rates of total mortality and cardiovascular events than those
whose night-to-day BP ratio was normal or extreme (Po0.0001).
Interpretation
In the IDACO database, the predictive accuracy of daytime and
nighttime BP and the night-to-day BP ratio depended on the disease
outcome under study and differed for fatal outcomes compared with
the composite of fatal and nonfatal diseases (Figure 1). For fatal end
points, nighttime BP performed better than the daytime BP, and the
night-to-day BP ratio predicted mortality. In contrast, for fatal
combined with nonfatal outcomes, the daytime BP performed equally
well as the nighttime BP and the night-to-day BP ratio lost its
prognostic accuracy.
Table 1 Characteristics of the study groups included in the IDACO
blood pressure variability analyses
Label
Day-to-night
variability24
Morning
surge35
Short-term
variability49
Total number available 9828 9488 11785
Exclusion criteria
Age o18 years old at enrollment 15 250 252
Conventional blood pressure not available 217
o10 daytime or o5 nighttime recordings 2138 2430 1892
o2 blood pressure readings before awaking 122
o2 blood pressure readings after awaking 1041
Missing readings during
3 consecutive hours 703
Number analyzed per ethnicity and country
Europe
Copenhagen, Denmark8 2137 1685 2018
Noorderkempen, Belgium9 1124 532 1086
Uppsala, Sweden15 1097 — 1069
Novosibirsk, Russia10 — 220 226
Padova, Italy11 — 290 303
Krako´w, Poland11 — 296 306
Pilsen, The Czech Republic11 — — 161
Dublin, Ireland55 — — 900
Asia
Ohasama, Japan12 1317 1396 1430
JingNing county, China6 349 327 346
South America
Montevideo, Uruguay13 1434 899 1093
Age, years (s.d.) 56.8
(13.9)
53.0
(14.7)
53.0
(15.8)
Women, n (%) 3416
(46%)
3048
(54%)
4785
(47%)
Hypertension, n (%) 3436
(46%)
2305
(41%)
3664
(41%)
Antihypertensive treatment, n
(% of hypertensives)
1637
(48%)
1188
(52%)
1749
(48%)
Median follow-up, years 9.6 11.4 11.3
Deaths, n 983 785 1242
Cardiovascular complications, n 943 611 1049
Abbreviation: IDACO, International Database on Ambulatory blood pressure in relation to
Cardiovascular Outcome.
An ellipsis indicates that the analysis did not include this cohort.
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The IDACO findings suggest that some of the associations between
outcome and nondipping might reflect reverse causality. Indeed, a less
pronounced nocturnal fall in BP might be a marker of physical
inactivity during daytime as a consequence of concurrent disease or
might result from the intake of BP-lowering drugs during daytime,
which lower BP during daytime but not at night. Furthermore,
participants with higher nighttime than daytime BP were not only
older at enrollment, but were also older when they died than were
those with a normal night-to-day ratio (78.2 vs. 74.1 years;
Po0.0001). Both cardiovascular (78.9 vs. 75.9 years; P¼0.002) and
noncardiovascular (77.5 vs. 73.6 years; P¼0.001) mortality contri-
buted to this finding. The worse prognosis for participants with higher
nighttime than daytime BP was therefore not associated with shorter
life expectancy.
Conclusion
The 24-h BP levels25 rather than the dipping pattern should continue
to inform clinical decisions. Furthermore, the classification of patients
according to the night-to-day BP ratio greatly depends on arbitrary
criteria, is poorly reproducible,26,27 and has a different prognostic
meaning according to the disease outcome under study, the prevailing
24-h BP level and treatment status. We would therefore recommend
that in future publications any categorical representation of the night-
to-day BP ratio is supported by continuous analyses adjusted for the
24-h BP and be stratified for treatment status.
THE MORNING SURGE IN BP
State-of-the-art before IDACO
Several studies have shown that the incidence of cardiovascular
complications peaks in the morning.28,29 For instance, in the Multi-
center Investigation of Limitation of Infarct Size Study28 and in the
Thrombolysis in Myocardial Infarction Phase II Trial,29 the incidence
of myocardial infarction was highest between 0600 and 1200hours. BP
also follows a circadian pattern, generally characterized by a fall during
sleep and a sharp rise upon awakening.30 This observation gave rise to
the hypothesis that an exaggerated morning surge of BP might predict
the cardiovascular outcome. However, previous studies of popula-
tions31 and hypertensive patients18,32,33 produced contradictory
results, possibly because of the small number of events and the lack
of statistical power. A further issue complicating the interpretation
of previous studies was the varying definitions of the morning surge
in BP.34
Information added by IDACO
For the analysis of morning surge,35 we selected studies in which the
participants completed a diary during ambulatory BP monitoring
(Table 1). Kario’s seminal paper,32 published in 2003, introduced the
definitions of the sleep-trough and pre-awakening morning surge in
BP as a method to study the risk associated with the rise in BP level on
awakening. For analysis of the morning surge in BP, we determined
the awake and asleep periods from the participants’ diary cards.
Participants were asked to record the time when they got up in the
morning and went to bed at night. The sleep-trough morning surge
was the difference between the morning pressure (the average BP
during the 2 h after awakening) and the lowest nighttime BP (the
average of the lowest pressure and the two readings immediately
preceding and following the lowest value).32 The pre-awakening
morning surge was the difference between the morning BP (the
average BP during the 2 h after awakening) and the pre-awakening
BP (the average BP during the 2 h before awakening).31,32
In all participants, the sleep-trough and pre-awakening morning
surge in systolic BP averaged 20.7±12.9 and 13.1±11.9mmHg,
respectively. However, there were significant ethnic and sex differences
in the morning BP surge. The mean values of the sleep-trough systolic
morning surge in the top decile were smaller in women than in
men among Europeans (40.9 vs. 43.2mmHg; P¼0.003) and South
Americans (38.8 vs. 41.5mmHg; P¼0.041), whereas the opposite was
the case among Asians (52.4 vs. 50.1mmHg; P¼0.064). For the
pre-awakening systolic morning surge, the differences between
women and men showed similar trends: 26.8 vs. 29.2mmHg
(P¼0.062), 22.5 vs. 26.9mmHg (P¼0.059) and 30.6 vs. 27.4mmHg
(P¼0.13) in Europeans, South Americans and Asians, respectively.
These differences explain why we applied ethnicity- and sex-specific
deciles to study the predictive value of the morning BP surge. This
also ensured an equal distribution of ethnicities and women and
men across the deciles. With adjustments applied for cohort, sex,
age, body mass index, the 24-h systolic BP, current smoking, use of
alcohol, serum cholesterol, the presence of diabetes mellitus, a history
Table 2 Adjusted standardized hazard ratios for mortality and for combined fatal and nonfatal cardiovascular end points
Label Total mortality Cardiovascular mortality All cardiovascular events Stroke Cardiac Coronary
Number of deaths or events (%) 983 (13.2) 387 (5.2) 943 (12.6) 420 (5.6) 525 (7.0) 390 (5.2)
Daytime blood pressure
Systolic 0.94 (0.87–1.03) 1.11 (0.98–1.27) 1.16 (1.07–1.26)z 1.27 (1.13–1.43)z 1.11 (0.99–1.24) 1.19 (1.04–1.36)*
Diastolic 0.94 (0.87–1.03) 1.07 (0.94–1.22) 1.11 (1.02–1.20)* 1.21 (1.07–1.37)w 1.04 (0.93–1.17) 1.11 (0.98–1.27)
Nighttime blood pressure
Systolic 1.22 (1.13–1.31)y 1.22 (1.09–1.36)z 1.21 (1.12–1.30)y 1.23 (1.11–1.37)z 1.17 (1.06–1.29)w 1.05 (0.93–1.18)
Diastolic 1.20 (1.11–1.30)y 1.24 (1.10–1.40)z 1.20 (1.11–1.30)y 1.24 (1.10–1.39)z 1.15 (1.04–1.28)w 1.08 (0.96–1.22)
Night-to-day blood pressure ratio
Systolic 1.13 (1.07–1.19)y 1.08 (0.99–1.17) 1.05 (0.98–1.11) 1.02 (0.94–1.11) 1.05 (0.97–1.14) 0.97 (0.89–1.07)
Diastolic 1.12 (1.06–1.19)z 1.10 (1.00–1.21)* 1.07 (1.00–1.13)* 1.04 (0.95–1.14) 1.07 (0.98–1.16) 1.00 (0.91–1.11)
Values are standardized hazard ratios (95% confidence intervals), which express the risk per s.d. increase in the blood pressure variables. Systolic or diastolic s.d.’s were 15.52/9.33 and 15.53/
9.25mmHg for the day and night blood pressures and 0.08/0.09 for the night-to-day blood pressure ratio. The cause of death was unknown in 36 cases. All hazard ratios were adjusted for cohort,
sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus and antihypertensive drug treatment. The daytime blood pressure was
additionally adjusted for the nighttime blood pressure (and vice versa), and the night-to-day ratio was additionally adjusted for the 24-h blood pressure.
Significance of the hazard ratios: *Po0.05, wPo0.01, zPo0.001 and yPo0.0001. Reproduced with permission from Boggia et al.24
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of cardiovascular disease and antihypertensive treatment, the risk
of noncardiovascular mortality (P¼0.04) and of all fatal combined
with nonfatal cardiac events (P¼0.03) was significantly higher in the
top decile of the sleep-trough morning surge compared with the
average risk in the whole study population (Table 3). When
additionally adjusted for the night-to-day ratio of systolic
BP, the risk of all-cause mortality was 32% (P¼0.004) higher in the
top decile of the sleep-trough morning surge (X37.0mmHg). For
cardiovascular and noncardiovascular death, these estimates were
18% (P¼0.30) and 42% (P¼0.005), and for all cardiovascular,
cardiac, coronary and cerebrovascular events, 30% (P¼0.01), 52%
(P¼0.004), 45% (P¼0.03) and 5% (P¼0.74), respectively (Table 3).
Similar results were found when analyzing the pre-awakening
morning surge.
In an attempt to define in a more precise manner the cut-off points
for risk stratification in clinical practice, we explored the risk asso-
ciated with all values of the sleep-trough and pre-awakening morning
surge in systolic BP within the 5th to 95th percentile interval. The
overall risk in the whole study population was used as reference
(Figure 2). For the sleep-trough morning surge in systolic BP, the
lower boundary of the 95% confidence interval (CI) of the risk
function crossed the unity of the HR at 24.6 and 20.9mmHg for
total mortality and all cardiovascular events, respectively. For the pre-
awakening morning surge in systolic BP these crossings occurred at
22.7 and 21.5mmHg, respectively. The results of these analyses
suggest that for both measures of the morning surge in systolic BP
a value below 20mmHg is probably not associated with increased risk
(Figure 2).
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Figure 1 Kaplan–Meier survival function estimates for total mortality (a) and for all cardiovascular (CV) events (b) by category of the night-to-day ratio of
systolic blood pressure. P-values are for trend across the four categories. Incidence was standardized to the distributions (mean or ratio) of cohort, sex, age,
body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease, diabetes mellitus and antihypertensive drug treatment.
Reproduced with permission from Boggia et al.24
Table 3 Multivariable-adjusted hazard ratios for the sleep-trough and pre-awakening morning surge in systolic blood pressure
Sleep-trough surge Pre-awakening surge
Outcomes (no. of events) Adjusted Fully adjusted Adjusted Fully adjusted
Mortality
All causes (785) 1.18 (0.99–1.42) 1.32 (1.09–1.59)w 1.11 (0.91–1.35) 1.23 (1.00–1.51)a
Cardiovascular (287) 1.06 (0.78–1.43) 1.18 (0.87–1.61) 1.08 (0.78–1.51) 1.22 (0.87–1.71)
Noncardiovascular (473) 1.28 (1.01–1.61)a 1.42 (1.11–1.80)w 1.13 (0.87–1.46) 1.23 (0.95–1.61)
Fatal and nonfatal events
All cardiovascular (611) 1.18 (0.97–1.44) 1.30 (1.06–1.60)a 1.31 (1.06–1.61)w 1.45 (1.17–1.80)z
Cardiac (317) 1.36 (1.04–1.78)a 1.52 (1.15–2.00)w 1.52 (1.14–2.01)w 1.69 (1.26–2.27)z
Coronary (228) 1.35 (0.98–1.85) 1.45 (1.04–2.03)a 1.50 (1.08–2.09)a 1.64 (1.16–2.49)w
Cerebrovascular (281) 0.89 (0.65–1.23) 0.95 (0.68–1.32) 1.04 (0.75–1.44) 1.13 (0.81–1.58)
Infarction (140) 0.79 (0.49–1.27) 0.85 (0.52–1.39) 1.26 (0.82–1.92) 1.46 (0.93–2.30)
Hemorrhage (70) 1.57 (0.90–2.73) 1.46 (0.81–2.63) 1.18 (0.64–2.18) 1.11 (0.59–2.11)
Hazard ratios (95% confidence intervals) express the risk in the top decile of the sleep-trough or pre-awakening morning surge in systolic blood pressure compared with the overall risk in the whole
study population. The 90th percentiles were determined after stratification for ethnicity and sex. The mean values of these cut-off points across ethnicities and sex weighted for the number of
participants in each of the strata were 37mmHg for the sleep-trough morning surge and 28mmHg for the pre-awakening morning surge. The Cox models included cohort, sex, age, body mass
index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus, antihypertensive drug treatment, 24-h systolic blood pressure and nine design variables coding
for the deciles. In fully adjusted models, the systolic night-to-day blood pressure ratio was additionally included in the Cox model. The cause of death was unknown in 25 cases. [2]Significance of
the hazard ratios: *Po0.05, wPo0.01, zPo0.001. Reproduced with permission from Li et al.35
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Interpretation
In 519 older hypertensive patients (mean age, 72 years) followed up
for 41 months, Kario et al.32 compared the risk of silent and clinical
cerebrovascular diseases in the top decile (X55mmHg) of the systolic
sleep-trough morning surge with the risk in the other patients. After
matching for age and the 24-h BP, the risk of multiple brain infarcts
was approximately two fold higher in patients belonging to the top
decile of the systolic sleep-trough morning surge. Moreover, with
adjustment for the 24-h BP, nocturnal dipping status and the
prevalence of silent infarcts at enrollment, the morning surge
remained a significant predictor of stroke.32
In 1430 participants (mean age, 61 years; 64% women) randomly
recruited from the Ohasama population, 128 cerebrovascular events
occurred during a mean follow-up of 10.4 years.31 The cerebrovascular
complications included 86 ischemic strokes and 27 cases with intra-
cerebral hemorrhage. With adjustments applied for the 24-h systolic
BP and other cardiovascular risk factors, the pre-awakening morning
surge in systolic pressure tended to be associated with an increased
risk of cerebral hemorrhage (HR per 1 s.d. increase, 1.34; 95% CI,
0.95–1.89), but not with the risk of ischemic stroke (0.97, 95% CI,
0.79–1.19). The predictive value of the sleep-trough morning surge
was broadly similar to that of the pre-awakening morning surge.31
Gosse et al.33 studied 507 untreated hypertensive patients without
complications at enrollment. The average follow-up period of these
patients was 92 months, during which 31 cardiovascular events,
including 6 deaths, occurred. The morning surge was the difference
between the first systolic measurement after standing up in the
morning and the last systolic value within the 30min before assuming
a standing position in the morning. A 1mmHg increase in the
morning surge, adjusted for the 24-h systolic BP and age, was
associated with a 3.3% increase (95% CI, 0.8–5.8%) in the risk of
cardiovascular events.33
In contrast to previous studies,31,32 in the IDACO database, the
morning surge in BP did not predict the stroke. It is likely that the
association between stroke and the morning surge depends on the
stroke subtype.31 In this study, Asians belonging to the top decile were
at a significantly higher risk for hemorrhagic stroke (51 cases; HR
(95% CI), 2.28 (1.09–4.26); P¼0.03), but not for ischemic stroke (127
cases; HR, 1.41 (0.67–2.98); P¼0.37), compared with Asians with a
lesser morning surge. These results were consistent with a previous
report from the Ohasama study,31 but different from Kario’s study,32 in
which the sleep-trough morning surge significantly predicted cerebral
infarcts. The different characteristics of the populations under study
might explain this diversity. Indeed, Kario’s study32 included older
hypertensive patients (mean age, 72 years). The sleep-trough morning
surge in systolic BP in the top decile (X55mmHg) was greater in
Kario’s study32 than in this report (X35mmHg in Europeans and
South Americans and X43mmHg in Asians).
Conclusion
Although the morning surge in systolic pressure as well as diastolic
pressure predicted the risk, we would suggest using only the rise in
systolic BP in the morning as a risk indicator, because in middle-aged
and older participants systolic rather than diastolic BP is the pre-
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Reproduced with permission from Li et al.35
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dominant risk factor.36 Using the morning surge in BP as a risk
indicator requires multiple BP readings during sleep and during the
pre-awakening and awakening periods. Participants also have to
complete a diary during ambulatory BP monitoring to report the
sleeping and awakening periods. In our database, these two issues
eliminated 4850 of 11 786 available participants. Moreover, according to
our recently published study in older patients with isolated systolic
hypertension,37 the morning surge in BP, irrespective of its definitions,
was poorly reproducible. Nearly 30% of the participants changed their
surge status either in the short term (median, 33 days) or in the long
term (median, 10 months).37 These three factors might limit the clinical
application of the morning surge in BP as a cardiovascular risk factor.
The IDACO findings established the prognostic value of the morn-
ing surge in BP in general populations. An exaggerated morning surge,
exceeding the 90th percentile of the population, is an independent risk
factor for mortality and cardiovascular and cardiac events. Conversely,
a sleep-trough or pre-awakening morning surge in systolic BP below
20mmHg is probably not associated with an increased risk of death or
cardiovascular events.
SHORT-TERM BP VARIABILITY
State-of-the-art before IDACO
The predictive value of short-term reading-to-reading BP variability
remains uncertain. Possible limitations of previous studies were lack of
statistical power,38–41 selection of specific groups of patients,41–43
categorization of variability by arbitrary cut-off points,38,40,43–45 and
sole reliance on fatal end points.46,47 Moreover, various parameters can
capture short-term BP variability over 24h, but most studies only
considered the s.d. of systolic40,42,48 or diastolic BP or both.44–46
Information added by IDACO
As measures of short-term reading-to-reading BP variability, we
used49 the s.d. over 24 h weighted for the time interval between
consecutive readings (s.d.24), the average of the daytime and nighttime
s.d.’s weighted for the duration of the daytime and nighttime interval
(s.d.dn),
50 and the average real variability weighted for the time
interval between consecutive readings (ARV24).
40 The s.d.dn is the
mean of day and night s.d. values corrected for the number of hours
included in each of these two periods (Figure 3a), according to the
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Figure 3 (a) Average of the daytime and nighttime s.d. weighted for the duration of the daytime and nighttime interval (s.d.dn), and (b) average real
variability weighted for the time interval between consecutive readings (ARV24). Reproduced with permission from Mena et al.
40 and Bilo et al.,50
respectively. (a) An illustrative 24-h systolic blood pressure (SBP) profile. The s.d. of the 24-h systolic BP is substantially higher than the corresponding
daytime and nighttime s.d.’s, separately computed, because of the contribution of the pronounced nocturnal fall in BP. ARV24 averages the absolute
differences between consecutive readings and thereby accounts for the order of the BP readings. (b) Illustrates that for distinct BP signals, s.d. can be the
same, whereas ARV24 is not. Reproduced with permission from Hansen et al.
49
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formula50 s.d.dn¼((day s.d.hours included in the daytime)+(night
s.d.hours included in the nighttime))/(hours included in daytime
plus nighttime). This method removes the influence of the day–night
BP difference from the estimate of BP variability. The ARV24 averages
the absolute differences of consecutive measurements and accounts in
this manner for the order in which the BP measurements are obtained
(Figure 3b). It is calculated by the following formula:
ARV ¼ 1
Sw
Xn1
k¼1
wjBPk+1  BPkj
where k ranges from 1 to N1 and w is the time interval between BPk
and BPk+1. N is the number of BP readings. The ARV24, s.d.24 and
s.d.dn were highly correlated with one another; the correlation coeffi-
cients ranged from 0.75 to 0.81 (Pp0.001) for systolic BP, and from
0.71 to 0.79 (Pp0.001) for diastolic BP.
In adjusted models not including 24-h BP level, systolic BP
variability predicted both total and cardiovascular mortality
(Table 4; Pp0.04), with the exception of s.d.24 in relation to total
mortality (P¼0.17). We obtained similar results after additional
adjustment for the 24-h systolic BP, with the exception of s.d.24 and
s.d.dn, which no longer predicted the cardiovascular mortality
(PX0.71). Diastolic BP variability predicted the total and cardiovas-
cular mortality both in adjusted and fully adjusted models (Table 4;
Pp0.002).
In adjusted analyses not including the 24-h BP level, systolic BP
variability predicted all of the fatal combined with nonfatal outcomes
(Pp0.03), with the exception of coronary events (PX0.07). However,
in fully adjusted analyses, systolic BP variability lost its predictive
value, with the exception of ARV24, in relation to all cardiovascular
events combined and stroke (Table 4). Diastolic BP variability was
predictive of all combined end points (Pp0.03), with the exception of
coronary events (PX0.15). In fully adjusted models, diastolic BP
variability only predicted all cardiovascular events combined (ARV24
and s.d.dn) and fatal plus nonfatal stroke (ARV24) (Table 4).
Figure 4 shows the absolute risk of a combined cardiovascular
events in relation to 24-h BP at different levels of systolic and diastolic
ARV24 (a and b) and in relation to ARV24 at different levels of 24-h
systolic and diastolic BP (c and d). The analyses were standardized to
the distributions (mean or ratio) of cohort, sex, age, 24-h heart rate,
body mass index, smoking and drinking, serum cholesterol, history of
cardiovascular disease, diabetes mellitus and treatment with antihy-
pertensive drugs. Absolute risk increased with both the 24-h BP
(Po0.001) and ARV24 (Pp0.04). However, with the 24-h BP in the
model, ARV24 added only 0.1% to the explained risk of a composite
cardiovascular event.49
Interpretation
Several prospective studies in populations40,46–48 and hypertensive
patients38,39,41–45 searched for association between cardiovascular out-
comes and BP variability, but reported inconsistent results. This might
be due to insufficient sample size, too few events, varying definitions
of the outcomes of interest or the use of different indexes of BP
variability. To assess BP variability, most studies used ambulatory BP
Table 4 Multivariable-adjusted standardized hazard ratios relating outcome to blood pressure variability
Systolic blood pressure Diastolic blood pressure
Outcome (number of events) s.d.24 s.d.dn ARV24 s.d.24 s.d.dn ARV24
s.d., mmHg 15.6 12.2 11.2 11.8 9.1 8.5
Mortality
Total (n¼1242)
Adjusted 1.05 (0.98–1.13) 1.13 (1.06–1.21)y 1.14 (1.06–1.22)y 1.11 (1.04–1.19)y 1.17 (1.09–1.24)y 1.12 (1.05–1.19)y
Fully adjusteda 1.00 (0.94–1.07) 1.08 (1.01–1.15)w 1.11 (1.04–1.18)y 1.09 (1.03–1.16)z 1.16 (1.09–1.23)y 1.13 (1.07–1.19)y
Cardiovascular (n¼487)
Adjusted 1.11 (1.00–1.24)w 1.13 (1.02–1.26)w 1.23 (1.11–1.36)y 1.21 (1.10–1.34)y 1.24 (1.13–1.36)y 1.27 (1.17–1.38)y
Fully adjusteda 1.03 (0.93–1.13) 1.05 (0.95–1.17) 1.17 (1.07–1.28)w 1.15 (1.05–1.26)z 1.18 (1.08–1.29)y 1.21 (1.12–1.31)y
Fatal and nonfatal events
Cardiovascular (n¼1049)
Adjusted 1.13 (1.06–1.22)y 1.15 (1.07–1.24)y 1.19 (1.11–1.27)y 1.15 (1.07–1.23)y 1.16 (1.09–1.24)y 1.16 (1.09–1.23)y
Fully adjusteda 1.02 (0.96–1.09) 1.04 (0.97–1.11) 1.07 (1.00–1.14)w 1.05 (0.99–1.12) 1.07 (1.01–1.14)w 1.07 (1.01–1.13)w
Cardiac (n¼577)
Adjusted 1.13 (1.02–1.24)w 1.11 (1.01–1.23)w 1.11 (1.00–1.22)w 1.10 (1.00–1.20)w 1.11 (1.02–1.21)y 1.10 (1.01–1.20)y
Fully adjusteda 1.03 (0.94–1.12) 1.01 (0.92–1.11) 1.03 (0.94–1.13) 1.02 (0.94–1.11) 1.03 (0.95–1.12) 1.02 (0.94–1.11)
Coronary (n¼421)
Adjusted 1.11 (0.99–1.24) 1.09 (0.97–1.22) 1.06 (0.94–1.19) 1.07 (0.96–1.19) 1.08 (0.97–1.19) 1.07 (0.97–1.19)
Fully adjusteda 1.07 (0.96–1.18) 1.04 (0.93–1.16) 1.03 (0.93–1.14) 1.02 (0.93–1.13) 1.02 (0.92–1.12) 1.02 (0.92–1.12)
Stroke (n¼457)
Adjusted 1.13 (1.01–1.26)w 1.16 (1.04–1.30)w 1.25 (1.13–1.39)y 1.22 (1.13–1.35)y 1.22 (1.10–1.35)y 1.26 (1.14–1.38)y
Fully adjusteda 0.98 (0.88–1.09) 1.03 (0.92–1.14) 1.10 (1.00–1.21)w 1.08 (0.99–1.19) 1.09 (0.99–1.20) 1.14 (1.05–1.23)w
Abbreviation: ARV, average real variability over 24h.
aAdditionally adjusted for the corresponding 24-h blood pressure level.
Values are standardized hazard ratios (95% confidence intervals), which express the risk per s.d. increase in the predictor variables. All hazard ratios were computed by Cox regression stratified for
cohort and adjusted for sex, age, 24-h heart rate, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus and treatment with antihypertensive
drugs.
Significance of the hazard ratios: wPo0.05, zPo0.01 and yPo0.001. Reproduced with permission from Hansen et al.49
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monitoring with intermittent readings at intervals ranging from 1545
to 3041min throughout 24h. In the Northwick Park study,39 the
investigators carried out continuous intra-arterial recordings, but did
not fully exploit the potential of this recording technique. Instead of
analyzing variability in the frequency domain, they computed hourly
means of BP and the within-participant s.d. of the hourly means as a
measure of each participant’s BP variability. In the Ohasama study,
investigators used the self-measured BP51 in addition to ambulatory
BP monitoring.46 In all but two studies,40,43 the researchers used the
s.d. of daytime, nighttime or 24-h BP as indexes of variability. Four
studies41,44–46 deliberately did not report on the predictive value
of the variability in the 24-h BP, because the diurnal BP profile also
includes long-term variability, which is captured by the night-to-day
BP ratio. To address this potential concern, we computed s.d.dn and
ARV24 as measures of variability. Only two other prospective studies,
one in a small general Venezuelan population (312 participants with
31 composite cardiovascular end points),40 and one in a hypertensive
population,43 implemented ARV24. Bilo et al.
50 were the first to
propose s.d.dn.
From a clinical point of view, the IDACO findings suggest that,
although statistically significant, the clinical applicability of BP varia-
bility for risk stratification might be limited. First, antihypertensive
drug treatment is bound to influence BP variability. Second,
the reproducibility of BP variability is poor. In 97 normotensive
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Figure 4 Ten-year absolute risk of combined cardiovascular (CV) events in relation to 24-h BP (a, b) at different levels of systolic and diastolic average real
variability over 24h (ARV24) and in relation to ARV24 (c, d) at different levels of 24-h systolic and diastolic blood pressure (BP). The analyses were
standardized to the distributions (mean or ratio) of cohort, sex, age, 24-h heart rate, body mass index, smoking and drinking, serum cholesterol, history of
cardiovascular disease, diabetes mellitus and treatment with antihypertensive drugs. Plotted values of 24-h BP (a, b) and ARV (c, d) span the 5th to 95th
percentile interval. The continuous risk functions correspond to the 5th, 25th, 50th, 75th and 95th percentiles of ARV (a, b) and 24-h BP (c, d). P-values
are for the independent effect of ARV (Parv) and 24-h BP (Pbp). np and ne indicate the number of participants at risk and the number of cardiovascular
events. Reproduced with permission from Hansen et al.49
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participants,52 the relative repeatability coefficient of the s.d. of the
24-h BP, expressed as a percentage of the 5th to 95th percentile
interval, was 13% systolic and 16% diastolic, whereas for the 24-h BP
these coefficients were 4 and 5%, respectively, lower values indicating
better reproducibility.52 Finally, the added value in terms of absolute
risk was modest in our population. For example, in adjusted analyses
(Figure 4), the increase in the 10-year absolute risk of a composite
cardiovascular event associated with an increase from the median to
the 75th percentile was 0.21% for systolic ARV24 (1.5mmHg) and
1.23% for the 24-h systolic BP (9.8mmHg). The corresponding
estimates for diastolic BP were 0.16% (2.3mmHg) and 1.05%
(5.8mmHg), respectively.
Conclusion
The IDACO report established that short-term reading-to-reading BP
variability is an independent risk factor, but, moreover, it also high-
lighted that the level of the 24-h BP remains the primary BP-related
risk factor to account for in clinical practice. For research making use
of intermittent techniques of ambulatory BP monitoring, our current
findings suggest that both s.d.dn and ARV24 might be useful measures,
but not the s.d. computed over the whole day, which also includes the
day–night BP difference.
PERSPECTIVES
Thus, the IDACO observations support the concept that the ambu-
latory BP should be recorded over the whole day, as both the
nighttime and daytime BP levels carry prognostic information. More-
over, the level of the 24-h BP remains the primary blood pressure-
related risk factor to account for in clinical practice. Notwithstanding
the new insights generated by the IDACO, several research questions
about the prognostic value of BP variability remain to be answered in
the future. First, chronotherapy53 means timing the administration of
antihypertensive drugs in such a way that the BP is lowered over 24h,
while a normal night-to-day BP ratio is preserved. However, there is
no evidence supporting the efficacy of chronotherapy in terms of BP
control54 or outcome.26 Second, the morning surge above the 90th
percentile significantly and independently predicted the cardiovascular
outcome and might contribute to risk stratification by ambulatory BP
monitoring. However, randomized clinical trials are needed to answer
the question whether restoring the diurnal BP profile might be
beneficial in terms of prevention of cardiovascular morbidity and
mortality. Finally, the value of BP variability in comparison with the
24-h BP level seems limited. However, in the setting of clinical
research, studies of BP variability will continue to generate meaningful
information.
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